MedTrace Logo

mRNA Based-Covid-19 Vaccine Effects on Blood Glucose Levels

NCT04923386 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2022-08-17

No results posted yet for this study

Summary

To determine if patients with a history of Diabetes Mellitus Type I or II developed a change in blood glucose levels as reported on Continuous glucose monitoring devices (CGMS) within the first week following administration of each dose of the COVID-19 vaccine.

Conditions

  • Diabetes Mellitus, Type 2
  • Diabetes Mellitus, Type 1
  • Hyperglycemia
  • Vaccine Adverse Reaction

Interventions

OTHER

None (not interventional)

This is not an intervention

Sponsors & Collaborators

  • Levenson, David I., M.D.

    lead INDIV

Principal Investigators

  • David I Levenson, M.D. · East Coast Medical Associates

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-15
Primary Completion
2021-12-15
Completion
2022-02-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04923386 on ClinicalTrials.gov